Array Biopharma Inc (ARRY.OQ) Quote| Reuters.com
Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

3.49USD
29 Jun 2016
Change (% chg)

$0.06 (+1.75%)
Prev Close
$3.43
Open
$3.52
Day's High
$3.54
Day's Low
$3.39
Volume
372,866
Avg. Vol
561,024
52-wk High
$7.37
52-wk Low
$2.38

ARRY.OQ

Chart for ARRY.OQ

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $492.01
Shares Outstanding(Mil.): 143.44
Dividend: --
Yield (%): --

Financials

  ARRY.OQ Industry Sector
P/E (TTM): -- 39.54 34.69
EPS (TTM): -0.57 -- --
ROI: -53.67 -6.70 14.13
ROE: -455.81 -6.13 15.35

BRIEF-Array Biopharma presents full results from Phase 3 NEMO study

* Study found binimetinib significantly extended median progression-free survival, at 2.8 months, versus 1.5 months observed with dacarbazine

Jun 06 2016

BRIEF-Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial

* Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage:

Jun 04 2016

Array Bio ends late-stage study of ovarian cancer drug

Array BioPharma Inc said it was abandoning a late-stage study testing its experimental ovarian cancer drug, after an interim analysis showed the trial would likely fail.

Apr 01 2016

UPDATE 1-Array Bio ends late-stage study of ovarian cancer drug

April 1 Array BioPharma Inc said it was abandoning a late-stage study testing its experimental ovarian cancer drug, after an interim analysis showed the trial would likely fail.

Apr 01 2016

BRIEF-Array BioPharma to discontinue MILO study in ovarian cancer

* Array BioPharma announces decision to discontinue MILO study in ovarian cancer

Apr 01 2016

BRIEF-Array Biopharma and Asahi Kasei Pharma announce collaboration for pain and inflammation program

* Co, Asahi Kasei Pharma corporation announce development and commercialization collaboration for novel pain and inflammation program

Mar 31 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.